Still Suffering? Why New IL-12/23 Inhibitors in the Pipeline May Be the Breakthrough You Need

If you're living with psoriasis, psoriatic arthritis, or another immune-mediated inflammatory condition, you already know the reality: treatments help many people—but not everyone. Some patients lose response over time. Others never achieve the level of skin clearance or symptom relief they hoped for.

That's why researchers continue to develop new IL-12/23 inhibitors in the pipeline. These next-generation therapies aim to improve effectiveness, durability, and safety—especially for people who haven't responded well to current biologic medications.

Let's break down what this means in practical, real-world terms.

---

Understanding IL-12 and IL-23 (In Plain Language)

Your immune system relies on chemical messengers called cytokines to coordinate inflammation. Two of these messengers—interleukin-12 (IL-12) and interleukin-23 (IL-23)—play a key role in driving inflammatory diseases such as:

• Plaque psoriasis
• Psoriatic arthritis
• Crohn's disease
• Ulcerative colitis

When IL-12 and IL-23 are overactive, they stimulate immune cells that attack healthy tissue. In psoriasis, this leads to:

• Thick, scaly skin plaques
• Redness and inflammation
• Itching or burning
• Sometimes joint pain

Blocking these pathways can dramatically reduce inflammation.

---

Where Current IL-12/23 Treatments Stand

The first major IL-12/23 inhibitor approved was ustekinumab, which blocks the shared p40 subunit of both IL-12 and IL-23. It has helped many patients achieve significant skin clearance and improved quality of life.

However, real-world experience and long-term studies show:

• Some patients do not reach complete or near-complete skin clearance
• Others gradually lose response
• Some switch to IL-23–specific inhibitors for better outcomes
• Certain inflammatory conditions respond better to more targeted approaches

This has led researchers to ask: Can we refine the science further?

---

Why Are New IL-12/23 Inhibitors in the Pipeline?

The goal of the new IL-12/23 inhibitors in the pipeline is not just to replicate older drugs—but to improve upon them.

Researchers are focusing on:

1. More Precise Targeting

Some newer agents are designed to:

• Target IL-23 more selectively
• Fine-tune immune modulation
• Minimize interference with protective immune responses

This precision may help reduce long-term side effects while improving effectiveness.

2. Improved Durability

New biologics are being studied for:

• Longer-lasting responses
• Fewer injections
• Better drug survival (meaning patients stay on them longer)

3. Enhanced Effectiveness for Resistant Cases

Clinical trials are examining how these medications perform in:

• Patients who failed prior biologics
• Those with moderate-to-severe psoriasis
• Individuals with both skin and joint involvement

4. Better Safety Profiles

Researchers continue to monitor:

• Infection risk
• Long-term immune effects
• Cardiovascular outcomes
• Cancer risk

So far, IL-12/23–targeting therapies have generally shown favorable safety profiles in large clinical trials, but ongoing monitoring is critical.

---

What Makes These Pipeline Therapies Different?

While many pipeline agents are still in clinical development, here's what sets them apart conceptually:

• Refined immune pathway targeting
• Potential combination pathway modulation
• Optimized dosing schedules
• Improved molecular design for longer half-life
• Enhanced response rates in clinical trials

Early and mid-stage trial data suggest that newer immune-targeting biologics may achieve:

• Higher rates of PASI 90 or PASI 100 (near or complete skin clearance)
• Faster onset of action
• Improved patient-reported outcomes

It's important to note that not every promising therapy in the pipeline reaches approval. Clinical trials are designed to confirm both effectiveness and safety before public use.

---

Who Might Benefit Most?

The new IL-12/23 inhibitors in the pipeline may be particularly relevant if you:

• Have moderate-to-severe plaque psoriasis
• Have failed one or more biologics
• Experience psoriatic arthritis along with skin symptoms
• Have inflammatory bowel disease plus psoriasis
• Want less frequent dosing

If you're unsure how severe your symptoms are or whether your current treatment is truly controlling your condition, Ubie's free AI-powered Psoriasis (Except for Pustular Psoriasis) symptom checker can help you assess your condition and better prepare for meaningful conversations with your healthcare provider.

---

Are There Risks?

No immune-modulating therapy is risk-free.

Because IL-12 and IL-23 are involved in immune defense, blocking them can increase susceptibility to infections. Most infections reported in clinical trials are mild (like upper respiratory infections), but serious infections can occur.

Other considerations include:

• Tuberculosis screening before treatment
• Monitoring for signs of infection
• Careful evaluation in people with a history of malignancy
• Vaccination review prior to starting therapy

The good news: Long-term extension studies of existing IL-12/23 inhibitors have shown reassuring safety data over many years for most patients.

Still, individual risk varies. This is why personal medical guidance is essential.

---

How Do These Compare to IL-23–Only Inhibitors?

In recent years, IL-23–specific inhibitors (targeting the p19 subunit) have become popular because they:

• Avoid blocking IL-12
• Show very high skin clearance rates
• Often require infrequent dosing

Some researchers believe selective IL-23 inhibition may provide stronger psoriasis control than dual IL-12/23 inhibition.

So why continue developing new IL-12/23 inhibitors?

Because:

• Some patients respond better to dual pathway blockade
• Certain inflammatory diseases may benefit from broader immune modulation
• The immune system is complex—one size does not fit all

Ongoing head-to-head and real-world studies will clarify which approach works best for specific patient groups.

---

The Bigger Picture: Personalized Treatment

The future of psoriasis care isn't just about stronger drugs—it's about better matching the right drug to the right patient.

Emerging research is exploring:

• Biomarkers that predict response
• Genetic patterns
• Immune cell profiling
• Personalized treatment algorithms

The new IL-12/23 inhibitors in the pipeline are part of this larger shift toward individualized therapy.

---

What Should You Do If You're Still Struggling?

If your psoriasis:

• Is not clearing despite treatment
• Keeps coming back
• Is affecting your joints
• Is interfering with work or relationships
• Is impacting your mental health

It may be time for a treatment reassessment.

Practical next steps:

• Track symptom severity
• Note flare triggers
• Review current medications
• Ask about biologic options or clinical trials
• Discuss whether newer therapies may be appropriate

Do not stop or change medications without medical supervision.

---

When to Speak to a Doctor Urgently

Seek immediate medical care if you experience:

• High fever with biologic therapy
• Persistent cough or shortness of breath
• Severe abdominal pain
• Signs of serious infection
• Sudden joint swelling and intense pain

Anything potentially life-threatening or serious should always be evaluated promptly by a medical professional.

---

The Bottom Line

If you're still suffering despite treatment, you are not alone—and you are not out of options.

The new IL-12/23 inhibitors in the pipeline represent an important evolution in immune-targeted therapy. While not every investigational drug will become available, the direction of research is clear:

• More precision
• Better durability
• Higher clearance rates
• Continued safety monitoring

For many patients, the future of psoriasis treatment looks increasingly hopeful.

Start by understanding your current symptom pattern with a thorough evaluation using Ubie's Psoriasis (Except for Pustular Psoriasis) assessment tool, and then speak with a qualified healthcare provider about whether newer therapies—or participation in clinical trials—might be right for you.

Psoriasis is chronic. But treatment is advancing. And progress matters.